🇺🇸 MR4 in United States

39 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 39

Most-reported reactions

1. Transplant Rejection — 6 reports (15.38%)
2. Pyrexia — 5 reports (12.82%)
3. Catheter Removal — 4 reports (10.26%)
4. Pneumonia — 4 reports (10.26%)
5. Pulmonary Embolism — 4 reports (10.26%)
6. Sepsis — 4 reports (10.26%)
7. Acute Kidney Injury — 3 reports (7.69%)
8. Renal Impairment — 3 reports (7.69%)
9. Transplant Failure — 3 reports (7.69%)
10. Urinary Tract Infection — 3 reports (7.69%)

Source database →

Frequently asked questions

Is MR4 approved in United States?

MR4 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for MR4 in United States?

Astellas Pharma Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.